Breaking Finance News

Pacific Biosciences of California (NASDAQ:PACB) has been upgraded to Hold in a report by Zacks Investment Research today.

Only yesterday Pacific Biosciences of California (NASDAQ:PACB) traded 0.00% even at $8.43. The company’s 50-day moving average is $8.70 and its 200-day moving average is $8.75. The last stock close price is down -2.81% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 0 shares of PACB changing hands under the typical 1,163,800

Zacks Investment Research has upgraded Pacific Biosciences of California (NASDAQ:PACB) to Hold in a report released on Monday October 17, 2016.

Performance Chart

Pacific Biosciences of California (NASDAQ:PACB)

With a total market value of $0, Pacific Biosciences of California has with a one year low of $6.76 and a one year high of $14.00 .

A total of 6 analysts have released a research note on PACB. Three analysts rating the company a strong buy, one analyst rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $12.50.

More About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *